




Instance: composition-en-efd5322cfb4c4cd93acfd97776160afe
InstanceOf: CompositionUvEpi
Title: "Composition for corlentor Package Leaflet"
Description:  "Composition for corlentor Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpefd5322cfb4c4cd93acfd97776160afe)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - corlentor"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Corlentor is and what it is used for </li>
<li>What you need to know before you take Corlentor </li>
<li>How to take Corlentor </li>
<li>Possible side effects </li>
<li>How to store Corlentor </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What corlentor is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What corlentor is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Corlentor (ivabradine) is a heart medicine used to treat:</p>
<ul>
<li>Symptomatic stable angina pectoris (which causes chest pain) in adult patients whose heart rate is 
over or equal to 70 beats per minute. It is used in adult patients who do not tolerate or cannot take 
heart medicines called beta-blockers. It is also used in combination with beta-blockers in adult 
patients whose condition is not fully controlled with a beta-blocker. </li>
<li>Chronic heart failure in adult patients whose heart rate is over or equal to 75 beats per minute. It 
is used in combination with standard therapy, including beta-blocker therapy or when beta-
blockers are contraindicated or not tolerated. </li>
</ul>
<p>About stable angina pectoris (usually referred to as  angina ): 
Stable angina is a heart disease which happens when the heart does not receive enough oxygen. The 
most common symptom of angina is chest pain or discomfort.  </p>
<p>About chronic heart failure : 
Chronic heart failure is a heart disease which happens when your heart cannot pump enough blood to 
the rest of your body. The most common symptoms of heart failure are breathlessness, fatigue, 
tiredness and ankle swelling. </p>
<p>How does Corlentor work? 
The specific heart rate lowering action of Corlentor helps:</p>
<ul>
<li>to control and reduce the number of angina attacks by lowering heart s need for oxygen, </li>
<li>to improve the heart functioning and vital prognosis in patients with chronic heart failure. </li>
</ul>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take corlentor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take corlentor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Corlentor 
- if you are allergic to ivabradine or any of the other ingredients of this medicine (listed in section 
6); 
- if your resting heart rate before treatment is too slow (below 70 beats per minute); 
- if you are suffering from cardiogenic shock (a heart condition treated in hospital); 
- if you suffer from a heart rhythm disorder (sick sinus syndrome, sino-atrial block, AV-block of 3rd 
degree); 
- if you are having a heart attack; 
- if you suffer from very low blood pressure; 
- if you suffer from unstable angina (a severe form in which chest pain occurs very frequently and 
with or without exertion); 
- if you have heart failure which has recently become worse; 
- if your heartbeat is exclusively imposed by your pacemaker; 
- if you suffer from severe liver problems; 
- if you are already taking medicines for the treatment of fungal infections (such as ketoconazole, 
itraconazole), macrolide antibiotics (such as josamycin, clarithromycin, telithromycin or 
erythromycin given orally), medicines to treat HIV infections (such as nelfinavir, ritonavir) or 
nefazodone (medicine to treat depression) or diltiazem, verapamil (used for high blood pressure or 
angina pectoris); 
- if you are a woman able to have children and not using reliable contraception; 
- if you are pregnant or trying to become pregnant; 
- if you are breast-feeding. </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Corlentor:</p>
<ul>
<li>if you suffer from heart rhythm disorders (such as irregular heartbeat, palpitation, increase in chest 
pain) or sustained atrial fibrillation (a type of irregular heartbeat), or an abnormality of 
electrocardiogram (ECG) called  long QT syndrome , </li>
<li>if you have symptoms such as tiredness, dizziness or shortness of breath (this could mean that 
your heart is slowing down too much), </li>
<li>if you suffer from symptoms of atrial fibrillation (pulse rate at rest unusually high (over 110 beats 
per minute) or irregular, without any apparent reason, making it difficult to measure), </li>
<li>if you have had a recent stroke (cerebral attack), </li>
<li>if you suffer from mild to moderate low blood pressure, </li>
<li>if you suffer from uncontrolled blood pressure, especially after a change in your antihypertensive 
treatment, </li>
<li>if you suffer from severe heart failure or heart failure with abnormality of ECG called  bundle 
branch block , </li>
<li>if you suffer from chronic eye retinal disease, </li>
<li>if you suffer from moderate liver problems, </li>
<li>if you suffer from severe renal problems. 
If any of the above applies to you, talk straight away to your doctor before or while taking Corlentor. </li>
</ul>
<p>Children 
Do not give this medicine to children and adolescents younger than 18 years. Available data are 
insufficient in this age group. </p>
<p>Other medicines and Corlentor 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>Make sure to tell your doctor if you are taking any of the following medicines, as a dose adjustment of 
Corlentor or monitoring should be required:</p>
<ul>
<li>fluconazole (an antifungal medicine) </li>
<li>rifampicin (an antibiotic) </li>
<li>barbiturates (for difficult sleeping or epilepsy) </li>
<li>phenytoin (for epilepsy) </li>
<li>Hypericum perforatum or St John s Wort (herbal treatment for depression) </li>
<li>
<p>QT prolonging medicines to treat either heart rhythm disorders or other conditions :</p>
</li>
<li>
<p>quinidine, disopyramide, ibutilide, sotalol, amiodarone (to treat heart rhythm disorders) </p>
</li>
<li>bepridil (to treat angina pectoris) </li>
<li>certain types of medicines to treat anxiety, schizophrenia or other psychoses (such as pimozide, 
ziprasidone, sertindole) </li>
<li>anti-malarial medicines (such as mefloquine or halofantrine) </li>
<li>intravenous erythromycin (an antibiotic) </li>
<li>pentamidine (an antiparasitic medicine) </li>
<li>cisapride (against the gastro-oesophageal reflux) </li>
<li>Some types of diuretics which may cause decrease in blood potassium level, such as furosemide, 
hydrochlorothiazide, indapamide (used to treat oedema, high blood pressure). </li>
</ul>
<p>Corlentor with food and drink<br />
Avoid grapefruit juice during treatment with Corlentor. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. 
Do not take Corlentor if you are pregnant or are planning to have a baby (see  Do not take 
Corlentor ).<br />
If you are pregnant and have taken Corlentor, talk to your doctor. 
Do not take Corlentor if you are able to become pregnant unless you use reliable contraceptive 
measures (see  Do not take Corlentor ). 
Do not take Corlentor if you are breast-feeding (see  Do not take Corlentor ). Talk to your doctor if 
you are breast-feeding or intending to breast-feed as breast-feeding should be discontinued if you take 
Corlentor. </p>
<p>Driving and using machines 
Corlentor may cause temporary luminous visual phenomena (a temporary brightness in the field of 
vision, see  Possible side effects ). If this happens to you, be careful when driving or using machines 
at times when there could be sudden changes in light intensity, especially when driving at night.  </p>
<p>Corlentor contains lactose 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take corlentor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take corlentor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure.<br />
Corlentor should be taken during meals. 
Corlentor 5mg tablet can be divided into equal doses.  </p>
<p>If you are being treated for stable angina pectoris 
The starting dose should not exceed one tablet of Corlentor 5 mg twice daily. If you still have angina 
symptoms and if you have tolerated the 5 mg twice daily dose well, the dose may be increased. The 
maintenance dose should not exceed 7.5 mg twice daily. Your doctor will prescribe the right dose for 
you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g. if 
you are aged 75 years or more), your doctor may prescribe half the dose i.e., one half 5 mg tablet of 
Corlentor 5 mg (corresponding to 2.5 mg ivabradine) in the morning and one half 5 mg tablet in the 
evening. </p>
<p>If you are being treated for chronic heart failure 
The usual recommended starting dose is one tablet of Corlentor 5 mg twice daily increasing if 
necessary to one tablet of Corlentor 7.5 mg twice daily. Your doctor will decide the right dose for you. 
The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g. if you are 
aged 75 years or more), your doctor may prescribe half the dose i.e., one half 5 mg tablet of Corlentor 
5 mg (corresponding to 2.5 mg ivabradine) in the morning and one half 5 mg tablet in the evening. </p>
<p>If you take more Corlentor than you should 
A large dose of Corlentor could make you feel breathless or tired because your heart slows down too 
much. If this happens, contact your doctor immediately. </p>
<p>If you forget to take Corlentor 
If you forget to take a dose of Corlentor, take the next dose at the usual time. Do not take a double 
dose to make up for the forgotten dose. 
The calendar printed on the blister containing the tablets should help you remember when you last 
took a tablet of Corlentor. </p>
<p>If you stop taking Corlentor 
As the treatment for angina or chronic heart failure is usually life-long, you should discuss with your 
doctor before stopping this medicinal product. 
If you think that the effect of Corlentor is too strong or too weak, talk to your doctor or pharmacist. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The most common adverse reactions with this medicine are dose dependent and related to its mode of 
action: </p>
<p>Very common (may affect more than 1 in 10 people) 
Luminous visual phenomena (brief moments of increased brightness, most often caused by sudden 
changes in light intensity). They can also be described as a halo, coloured flashes, image 
decomposition or multiple images. They generally occur within the first two months of treatment after 
which they may occur repeatedly and resolve during or after treatment </p>
<p>Common (may affect up to 1 in 10 people) 
Modification in the heart functioning (the symptoms are a slowing down of the heart rate). They 
particularly occur within the first 2 to 3 months of treatment initiation. </p>
<p>Other side effects have also been reported: </p>
<p>Common (may affect up to 1 in 10 people) 
Irregular rapid contraction of the heart (Atrial fibrillation), abnormal perception of heartbeat 
(Bradycardia, Ventricular extrasystoles, AV 1st degree block (ECG prolonged PQ interval)), 
uncontrolled blood pressure, headache, dizziness and blurred vision (cloudy vision). </p>
<p>Uncommon (may affect up to 1 in 100 people) 
Palpitations and cardiac extra beats, feeling sick (nausea), constipation, diarrhoea, abdominal pain, 
spinning sensation (vertigo), difficulty breathing (dyspnoea), muscle spasms, high blood levels of uric 
acid, an excess of eosinophils (a type of white blood cell) and elevated creatinine in blood (a 
breakdown product of muscle), skin rash, angioedema (such as swollen face, tongue or throat, 
difficulty in breathing or swallowing), low blood pressure, fainting, feeling of tiredness, feeling of 
weakness, abnormal ECG heart tracing, double vision, impaired vision. </p>
<p>Rare (may affect up to 1 in 1,000 people) 
Urticaria, itching, skin reddening, feeling unwell. </p>
<p>Very rare (may affect up to 1 in 10,000 people) 
Irregular heart beats (AV 2nd degree block, AV 3rd degree block, Sick sinus syndrome). </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store corlentor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store corlentor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after  EXP . 
The expiry date refers to the last day of that month. </p>
<p>This medicinal product does not require any special storage conditions. </p>
<p>Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Corlentor contains 
- The active substance is ivabradine (as hydrochloride). </p>
<p>Corlentor 5 mg film-coated tablets:  </p>
<p>each film-coated tablet contains 5 mg ivabradine (as hydrochloride). </p>
<p>Corlentor 7.5 mg film-coated tablets: </p>
<p>each film-coated tablet contains 7.5 mg ivabradine (as hydrochloride). </p>
<ul>
<li>
<p>The other ingredients are:</p>
</li>
<li>
<p>tablet core: lactose monohydrate, magnesium stearate (E 470 B), maize starch, maltodextrin, 
colloidal anhydrous silica (E 551) </p>
</li>
<li>film coating: hypromellose (E 464), titanium dioxide (E 171), macrogol (6000), glycerol (E 
422), magnesium stearate (E 470 B), yellow iron oxide (E 172), red iron oxide (E 172). </li>
</ul>
<p>What Corlentor looks like and contents of the pack 
Corlentor 5 mg tablets are salmon-coloured, oblong film-coated tablets scored on both sides, engraved 
with  5  on one face and 
on the other. 
Corlentor 7.5 mg tablets are salmon-coloured, triangular, film-coated tablets engraved with  7.5  on 
one face and 
on the other. </p>
<p>The tablets are available in calendar packs (Aluminium/PVC blisters) of 14, 28, 56, 84, 98, 100 or tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Les Laboratoires Servier 
50, rue Carnot<br />
92284 Suresnes cedex - France </p>
<p>Manufacturer 
Les Laboratoires Servier Industrie 
905 route de Saran 
45520 Gidy   France </p>
<p>Servier (Ireland) Industries Ltd 
Gorey Road 
Arklow - Co. Wicklow 
Ireland </p>
<p>Przedsiebiorstwo Farmaceutyczne ANPHARM S.A. 
ul. Annopol 6B   03-236 Warszawa<br />
Poland </p>
<p>Laboratorios Servier, S.L. 
Avda. de los Madro os, 28043 Madrid 
Spain </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder. </p>
<p>Belgi /Belgique/Belgien 
S.A. Servier Benelux N.V. 
T l/Tel: +32 (0)2 529 43 Lietuva 
UAB  SERVIER PHARMA<br />
Tel: +370 (5) 2 63 86   </p>
<p>.: +359 2 921 57 Luxembourg/Luxemburg 
S.A. Servier Benelux N.V. 
T l/Tel: +32 (0)2 529 43  esk  republika 
Servier s.r.o. 
Tel: +420 222 118 Magyarorsz g 
Servier Hungaria Kft. 
Tel.: + 36 1 238 77 Danmark 
Servier Danmark A/S 
Tlf: +45 36 44 22 Malta 
V.J. Salomone Pharma Ltd<br />
Tel: + 356 21 22 01 Deutschland 
Servier Deutschland GmbH 
Tel: +49 (0)89 57095 Nederland 
Servier Nederland Farma B.V. 
Tel: +31 (0)71 5246Eesti 
Servier Laboratories O <br />
Tel:+ 372 664 5Norge 
Servier Danmark A/S 
Tlf: +45 36 44 22   </p>
<p>: +30 210 939 1 sterreich 
Servier Austria GmbH 
Tel: +43 (1) 524 39 Espa a 
DANVAL S.A. 
Tel: +34 91 748 96 Polska 
Servier Polska SP. Z O.O. 
Tel.: + 48 (0) 22 594 90 France 
Les Laboratoires Servier 
T l: +33 (0)1 55 72 60 Portugal 
Servier Portugal, Lda 
Tel: +351 21 312 20 Hrvatska 
Servier Pharma, d. o. o. 
Tel.: +385 (0)1 3016 Rom nia 
Servier Pharma SRL 
Tel: +4 021 528 52 Ireland 
Servier Laboratories (Ireland) Ltd. 
Tel: +353 (0)1 663 8Slovenija 
Servier Pharma d.o.o. 
Tel: + 386 (0)1 563 48  sland 
Servier Laboratories 
C/o Icepharma hf 
S mi: +354 540 8Slovensk  republika 
Servier Slovensko spol. s r.o. 
Tel: +421 (0) 2 5920 41 Italia 
Istituto Farmaco Biologico Stroder S.r.l. 
Tel: +39 06 669Suomi/Finland 
Servier Finland Oy 
P. /Tel: +358 (0)9 279 80 <br />
C.A. Papaellinas Ltd. 
 : +357 22741Sverige 
Servier Sverige AB 
Tel: +46(8)5 225 08 Latvija 
SIA Servier Latvia 
Tel: + 371 6750 2United Kingdom (Northern Ireland) 
Servier Laboratories (Ireland) Ltd 
Tel: +44 (0)1753 666This leaflet was last revised in  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-efd5322cfb4c4cd93acfd97776160afe
InstanceOf: CompositionUvEpi
Title: "Composition for corlentor Package Leaflet"
Description:  "Composition for corlentor Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpefd5322cfb4c4cd93acfd97776160afe)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - corlentor"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal De vide, før De begynder at tage Corlentor 
3. Sådan skal De tage Corlentor 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What corlentor is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What corlentor is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Corlentor (ivabradin) er hjertemedicin, som anvendes til behandling af:</p>
<ul>
<li>Symptomerne ved stabil angina pectoris (en lidelse, som forårsager smerter i brystet) hos voksne 
patienter med en puls på mindst 70 slag i minuttet. Det anvendes til voksne patienter, som ikke 
kan tåle eller ikke kan anvende hjertemedicin af typen betablokkere. Det anvendes også i 
kombination med betablokkere til voksne patienter, hvis sygdom ikke er fuldstændigt kontrolleret 
med en betablokker. </li>
<li>Kronisk hjertesvigt hos voksne patienter med en puls på mindst 75 slag i minuttet. Corlentor 
bruges sammen med standardbehandling med betablokker, eller når patienten ikke må få eller 
ikke kan tåle betablokker. </li>
</ul>
<p>Stabil angina pectoris (også kaldet "hjertekrampe"): 
Stabil hjertekrampe er en hjertesygdom, som opstår, når hjertet ikke får tilstrækkeligt med ilt. De mest 
almindelige symptomer på hjertekrampe er smerter eller ubehag i brystet.  </p>
<p>Kronisk hjertesvigt: 
Kronisk hjertesvigt er en hjertesygdom, der opstår, når hjertet ikke kan pumpe tilstrækkeligt blod 
rundt til resten af kroppen. De almindeligste symptomer på hjertesvigt er åndenød, træthed, udmattelse 
og hævede ankler. </p>
<p>Sådan virker Corlentor 
Ivabradins specifikke pulsenedsættende virkning hjælper:</p>
<ul>
<li>med at kontrollere og mindske antallet af anfald af hjertekrampe ved at nedsætte hjertets 
behov for ilt, </li>
<li>med at forbedre hjertefunktionen og prognosen hos patienter med kronisk hjertesvigt. </li>
</ul>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take corlentor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take corlentor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Corlentor 
- hvis De er allergisk over for ivabradin eller et af de øvrige indholdsstoffer i Corlentor (angivet i 
punkt 6) 
- hvis Deres puls i hvile før behandlingen er for langsom (under 70 slag i minuttet) 
- hvis De lider af kardiogent shock (en hjertesygdom, som skal behandles på hospital) 
- hvis De lider af forstyrrelser i hjertets rytme  (syg sinus-syndrom, sinoatrialt blok, 3. grads 
AV-blok) 
- hvis De får et hjerteanfald 
- hvis De lider af meget lavt blodtryk 
- hvis De lider af ustabil hjertekrampe (en alvorlig form med hyppige brystsmerter, der opstår 
både under hvile og anstrengelse) 
- hvis De lider af hjertesvigt, og Deres tilstand for nylig er forværret 
- hvis Deres hjerterytme udelukkende styres af en pacemaker 
- hvis De lider af svære leverproblemer 
- hvis De allerede tager medicin til behandling af svampeinfektioner (fx ketoconazol, 
itraconazol), makrolidantibiotika (fx josamycin, clarithromycin, telithromycin eller 
erythromycin givet oralt) eller medicin til behandling af hiv-infektioner (som fx nelfinavir, 
ritonavir) eller nefazodon (medicin til behandling af depressioner) eller diltiazem, verapamil 
(bruges til for højt blodtryk eller angina pectoris) 
- hvis De er en kvinde i den fødedygtige alder og ikke anvender sikker prævention 
- hvis De er gravid eller forsøger at blive gravid 
- hvis De ammer. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før De tager Corlentor 
- hvis De lider af forstyrrelser i hjertets rytme (uregelmæssig puls, hjertebanken, smerter i 
brystkassen) eller vedvarende hjerteflimmer (hurtig, meget uregelmæssig puls) eller en 
abnormitet i elektrokardiogrammet (ekg) kaldet "lang QT-syndrom" 
- hvis De har symptomer som træthed, svimmelhed eller kortåndethed (det kan betyde, at Deres 
hjerte slår for langsomt) 
-<br />
hvis De lider af symptomer på artrieflimren (hvilepulsen er usædvanlig høj (over 110 slag i 
minuttet) eller uregelmæssig uden nogen tydelig grund, hvilket gør det vanskeligt at måle 
pulsen) 
- hvis De for nylig har haft et slagtilfælde (blodprop i hjernen/hjerneblødning) 
- hvis De lider af lavt blodtryk i let til moderat grad 
- hvis Deres blodtryk ikke er under kontrol - især efter en ændring i Deres blodtryksbehandling 
- hvis De lider af alvorligt hjertesvigt eller hjertesvigt med en abnormitet i ekg kaldet "grenblok" 
- hvis De lider af en kronisk nethindesygdom i øjet 
- hvis De lider af moderate leverproblemer 
- hvis De lider af svære problemer med nyrerne 
Hvis noget af ovenstående gælder for Dem, skal De straks tale med Deres læge om det, før eller mens 
De tager Corlentor. </p>
<p>Børn 
Lægemidlet må ikke gives til børn og unge under 18 år. Der findes ikke tilstrækkelige data hos denne 
aldersgruppe. </p>
<p>Brug af anden medicin sammen med Corlentor 
Fortæl altid lægen eller apotekspersonalet, hvis De tager anden medicin, for nylig har taget anden 
medicin eller planlægger at tage anden medicin. </p>
<p>Det er vigtigt, at De fortæller det til Deres læge, hvis De tager nogle af følgende lægemidler, da det 
kan blive nødvendigt at justere dosis af Corlentor eller kontrollere Dem nøjere:</p>
<ul>
<li>fluconazol (mod svampeinfektioner) </li>
<li>rifampicin (antibiotikum) </li>
<li>barbiturater (for søvnforstyrrelser eller epilepsi) </li>
<li>phenytoin (for epilepsi) </li>
<li>Hypericum perforatum eller perikon (naturmedicin for depression) </li>
<li>
<p>medicin, der forlænger QT-intervallet i ekg til behandling af enten hjerterytmeforstyrrelser eller 
andre sygdomme, som fx:</p>
</li>
<li>
<p>quinidin, disopyramid, ibutilid, sotalol, amiodaron (til behandling af forstyrrelser af hjertets 
rytme) </p>
</li>
<li>bepridil (til behandling af angina pectoris) </li>
<li>visse lægemidler til behandling af angst, skizofreni eller andre alvorlige sindslidelser (fx 
pimozid, ziprasidon og sertindol) </li>
<li>malariamidler (fx mefloquin eller halofantrin) </li>
<li>intravenøs erythromycin (et antibiotikum) </li>
<li>pentamidin (et lægemiddel mod parasitter) </li>
<li>cisaprid (mod mavesyre-reflux fra mavesæk til spiserør)  </li>
<li>nogle typer vanddrivende medicin (diuretika), der kan medføre nedsat kaliumniveau i blodet, 
såsom furosemid, hydrochlorthiazid, indapamid (anvendt til at behandle ødemer og højt 
blodtryk). </li>
</ul>
<p>Brug af Corlentor sammen med mad og drikke 
Undgå grapefrugtjuice under behandling med Corlentor. </p>
<p>Graviditet og amning 
Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apotekspersonalet til råds, før De tager dette lægemiddel. 
De må ikke tage Corlentor, hvis De er gravid eller planlægger at blive gravid (se under "Tag ikke 
Corlentor"). 
Tal med Deres læge, hvis De er gravid og har taget Corlentor.<br />
Tag ikke Corlentor, hvis De kan blive gravid, medmindre De anvender sikker prævention (se "Tag 
ikke Corlentor"). 
De må ikke tage Corlentor, hvis De ammer (se under "Tag ikke Corlentor"). Tal med lægen, hvis De 
ammer eller ønsker at amme, da amning skal ophøre, hvis De tager Corlentor. </p>
<p>Trafik- og arbejdssikkerhed 
Corlentor kan forårsage forbigående lysfænomener (forbigående lysglimt i synsfeltet, se under 
"Bivirkninger"). Hvis De får det, skal De udvise forsigtighed, når De kører bil eller betjener maskiner, 
specielt på tidspunkter, hvor der kan forekomme pludselige ændringer i lysintensiteten, især ved 
nattekørsel.  </p>
<p>Corlentor indeholder lactose 
Kontakt lægen, før De tager dette lægemiddel, hvis lægen har fortalt Dem, at De ikke tåler visse 
sukkerarter. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take corlentor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take corlentor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er De i tvivl, så spørg 
lægen eller apotekspersonalet.<br />
Corlentor skal helst tages under et måltid. 
Corlentor 5 mg tablet kan deles i to lige store doser. </p>
<p>Hvis De bliver behandlet for stabil angina pectoris 
Startdosis bør ikke være mere end en Corlentor-tablet på 5 mg to gange dagligt. Hvis De stadig har 
symptomer på angina og hvis De har tålt dosis på 5 mg to gange dagligt godt, kan dosis øges. 
Vedligeholdelsesdosis bør ikke være højere end 7,5 mg to gange dagligt. Deres læge vil ordinere den 
rette dosis til Dem. Den sædvanlige dosis er en tablet om morgenen og en tablet om aftenen. I nogle 
tilfælde (fx hvis De er  75 år eller derover) kan Deres læge halvere dosis, dvs. en halv Corlentor-tablet 
på 5 mg (svarende til 2,5 mg ivabradin) om morgenen og en halv tablet på 5 mg om aftenen. </p>
<p>Hvis De bliver behandlet for kronisk hjertesvigt 
Den sædvanlige startdosis er en Corlentortablet på 5 mg to gange daglig, og den kan om nødvendigt 
øges til en Corlentortablet på 7,5 mg to gange daglig. Deres læge fastsætter den rette dosis til Dem. 
Den sædvanlige dosis er en tablet om morgenen og en tablet om aftenen. I nogle tilfælde (fx hvis De 
er 75 år eller derover) kan Deres læge halvere dosis, dvs. en halv Corlentortablet på 5 mg (svarende til 
2,5 mg ivabradin) om morgenen og en halv tablet på 5 mg om aftenen. </p>
<p>Hvis De har taget for meget Corlentor<br />
En stor dosis Corlentor kan få Dem til at føle Dem kortåndet eller træt, fordi Deres hjerte slår for 
langsomt. Hvis det sker, skal De straks kontakte Deres læge.  </p>
<p>Hvis De har glemt at tage Corlentor 
Hvis De glemmer at tage en dosis Corlentor, skal De tage den næste dosis til normal tid. De må ikke 
tage en dobbeltdosis som erstatning for den glemte dosis. 
Kalenderen på blisteren, som indeholder tabletterne, skal hjælpe Dem med at huske, hvornår De sidst 
tog en Corlentor tablet. </p>
<p>Hvis De holder op med at tage Corlentor 
Behandlingen for angina pectoris og kronisk hjertesvigt er sædvanligvis livslang. Tal med Deres læge, 
før De holder op med at tage denne medicin. 
Tal med Deres læge eller apotekspersonalet, hvis De mener, at virkningerne af Corlentor er for 
kraftige eller for svage. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>De almindeligste bivirkninger med dette lægemiddel er dosisafhængige og relaterede til dets 
virkningsmåde: 
Meget almindelig  (kan forekomme hos flere end 1 ud af 10 personer) 
Lysfænomener (kortvarige lysglimt, der ofte skyldes pludselige forandringer i lysets intensitet). De 
kan også beskrives som en ring, farvede lysglimt, billedopløsning eller mangfoldige billeder. De 
forekommer almindeligvis inden for de første to måneder af behandlingen, hvorefter de kan 
forekomme gentagne gange og forsvinde under eller efter behandlingen.  </p>
<p>Almindelig (kan forekomme hos op til 1 ud af 10 personer) 
Forandringer i hjertets funktion (viser sig ved, at pulsen bliver langsommere). De forekommer især 
inden for de første 2 til 3 måneder efter indledning af behandlingen. </p>
<p>Andre bivirkninger er også blevet rapporteret: 
Almindelig (kan forekomme hos op til 1 ud af 10 personer) 
Uregelmæssig hurtig sammentrækning af hjertet (atrieflimren), unormal fornemmelse af hjerteslag 
(bradykardi, ventrikulære ekstrasystoler, AV-blok af 1. grad (forlænget PQ-interval på ekg)), 
ukontrolleret blodtryk, hovedpine, svimmelhed og uskarpt syn (uklart syn). </p>
<p>Ikke almindelig  (kan forekomme hos op til 1 ud af 100 personer) 
Hjertebanken og ekstra hjerteslag, kvalme, forstoppelse, diarré, mavesmerter, fornemmelse af at 
verden drejer rundt (vertigo), åndedrætsbesvær (kortåndethed), muskelspasmer, forhøjet urinsyre i 
blodet, for mange hvide blodlegemer (af typen eosinofile granulocytter) og forhøjede blodværdier for 
kreatinin (et nedbrydningsprodukt, som dannes i musklerne), hududslæt, angioødem (viser sig som 
hævelser i ansigt, tunge eller hals eller besvær med at trække vejret eller synke), lavt blodtryk, 
besvimelse, træthed, svaghed, abnorm ekg-diagram, dobbeltsyn, nedsat syn. </p>
<p>Sjælden (kan forekomme hos op til 1 ud af 1.000 personer) 
Nældefeber, kløe, rødme af huden, utilpashed. </p>
<p>Meget sjælden (kan forekomme hos op til 1 ud af 10.000 personer) 
Uregelmæssig puls (AV-blok af 2. grad, AV-blok af 3. grad, syg sinus-syndrom). </p>
<p>Indberetning af bivirkninger<br />
Hvis De oplever bivirkninger, bør De tale med Deres læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store corlentor"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store corlentor"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på kartonen og blisteren efter Exp. Udløbsdatoen 
er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg apotekspersonalet, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Corlentor indeholder:</p>
<ul>
<li>Aktivt stof: ivabradin (som hydrochlorid) </li>
</ul>
<p>Corlentor 5 mg filmovertrukne tabletter: Hver filmovertrukket tablet indeholder 5 mg ivabradin 
(som hydrochlorid). </p>
<p>Corlentor 7,5 mg filmovertrukne tabletter: Hver filmovertrukket tablet indeholder 7,5 mg 
ivabradin (som hydrochlorid). 
- Øvrige indholdsstoffer:</p>
<ul>
<li>tabletkerne: lactosemonohydrat, magnesiumstearat (E 470 B), majsstivelse, maltodextrin, 
kolloid vandfri silica (E 551) </li>
<li>filmovertræk: hypromellose (E 464), titandioxid (E 171), macrogol (6000), glycerol (E 422), 
magnesiumstearat (E 470 B), gul jernoxid (E 172), rød jernoxid (E 172).  </li>
</ul>
<p>Udseende og pakningsstørrelser 
Corlentor 5 mg tabletter er laksefarvede, aflange filmovertrukne tabletter med delekærv på begge 
sider, mærket med "5" på den ene side og 
 på den anden. 
Corlentor 7,5 mg tabletter er laksefarvede, trekantede filmovertrukne tabletter, mærket med "7.5" på 
den ene side og 
 på den anden.  </p>
<p>Tabletterne fås i kalenderpakninger (blisterkort af aluminium/PVC) med 14, 28, 56, 84, 98, 100 eller 
112 tabletter. 
Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Les Laboratoires Servier 
50, rue Carnot 
92284 Suresnes cedex 
Frankrig </p>
<p>Fremstiller 
Les Laboratoires Servier 
905 route de Saran 
F-45520 Gidy 
Frankrig </p>
<p>Servier (Ireland) Industries Ltd 
Gorey Road 
Arklow - Co. Wicklow 
Irland </p>
<p>Przedsiebiorstwo Farmaceutyczne ANPHARM S.A. 
ul. Annopol 6B -<br />
PL-03-236 Warszawa 
Polen </p>
<p>Laboratorios Servier, S.L. 
Avda. de los Madroños, 28043 Madrid 
Spanien </p>
<p>Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
S.A. Servier Benelux N.V. 
Tél/Tel: +32 (0)2 529 43 Lietuva 
UAB "SERVIER PHARMA" 
Tel: +370 (5) 2 63 86<br />
България 
Сервие Медикал ЕООД 
Тел.: +359 2 921 57<br />
Luxembourg/Luxemburg 
S.A. Servier Benelux N.V. 
Tél/Tel: +32 (0)2 529 43<br />
Česká republika 
Servier s.r.o. 
Tel: +420 222 118<br />
Magyarország 
Servier Hungaria Kft. 
Tel.: + 36 1 238 77<br />
Danmark 
Servier Danmark A/S 
Tlf: +45 36 44 22<br />
Malta 
V.J. Salomone Pharma Ltd<br />
Tel: + 356 21 22 01 <br />
Deutschland 
Servier Deutschland GmbH 
Tel: +49 (0)89 57095 Nederland 
Servier Nederland Farma B.V. 
Tel: +31 (0)71 5246 
Eesti 
Servier Laboratories OÜ<br />
Tel:+ 372 664 5 
Norge 
Servier Danmark A/S 
Tlf: +45 36 44 22<br />
Ελλάδα 
ΣΕΡΒΙΕ ΕΛΛΑΣ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΠΕ 
Τηλ: +30 210 939 1Österreich 
Servier Austria GmbH 
Tel: +43 (1) 524 39<br />
España 
DANVAL S.A. 
Tel: +34 91 748 96<br />
Polska 
Servier Polska SP. Z O.O. 
Tel.: + 48 (0) 22 594 90<br />
France 
Les Laboratoires Servier 
Tél: +33 (0)1 55 72 60 Portugal 
Servier Portugal, Lda 
Tel: +351 21 312 20<br />
Hrvatska 
Servier Pharma, d. o. o. 
Tel.: +385 (0)1 3016<br />
România 
Servier Pharma SRL 
Tel: +4 021 528 52<br />
Ireland 
Servier Laboratories (Ireland) Ltd. 
Tel: +353 (0)1 663 8 
Slovenija 
Servier Pharma d.o.o. 
Tel: + 386 (0)1 563 48 Ísland 
Servier Laboratories 
C/o Icepharma hf 
Sími: +354 540 8 
Slovenská republika 
Servier Slovensko spol. s r.o. 
Tel: +421 (0) 2 5920 41 Italia 
Istituto Farmaco Biologico Stroder S.r.l. 
Tel: +39 06 669 
Suomi/Finland 
Servier Finland Oy 
P./Tel: +358 (0)9 279 80<br />
Κύπρος 
C.A. Papaellinas Ltd. 
Τηλ: +357 22741Sverige 
Servier Sverige AB 
Tel: +46(8)5 225 08<br />
Latvija 
SIA Servier Latvia 
Tel: + 371 6750 2 
United Kingdom (Northern Ireland) 
Servier Laboratories (ireland) Ltd 
Tel: +44 (0)1753 666 
Denne indlægsseddel blev senest ændret 
De kan finde yderligere oplysninger om Corlentor på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-efd5322cfb4c4cd93acfd97776160afe
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for corlentor Package Leaflet for language en"
Description: "ePI document Bundle for corlentor Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-efd5322cfb4c4cd93acfd97776160afe"
* entry[0].resource = composition-en-efd5322cfb4c4cd93acfd97776160afe

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpefd5322cfb4c4cd93acfd97776160afe"
* entry[=].resource = mpefd5322cfb4c4cd93acfd97776160afe
                            
                    
Instance: bundlepackageleaflet-da-efd5322cfb4c4cd93acfd97776160afe
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for corlentor Package Leaflet for language da"
Description: "ePI document Bundle for corlentor Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-efd5322cfb4c4cd93acfd97776160afe"
* entry[0].resource = composition-da-efd5322cfb4c4cd93acfd97776160afe

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpefd5322cfb4c4cd93acfd97776160afe"
* entry[=].resource = mpefd5322cfb4c4cd93acfd97776160afe
                            
                    



Instance: mpefd5322cfb4c4cd93acfd97776160afe
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Corlentor 5 mg film-coated tablets"
Description: "Corlentor 5 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "Corlentor 5 mg film-coated tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Corlentor 5 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: efd5322cfb4c4cd93acfd97776160afeListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "corlentor"

* status = #current
* mode = #working

* title = "List of all ePIs associated with corlentor"

* subject = Reference(mpefd5322cfb4c4cd93acfd97776160afe)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#corlentor "corlentor"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-efd5322cfb4c4cd93acfd97776160afe) // corlentor en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-efd5322cfb4c4cd93acfd97776160afe) // corlentor da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-efd5322cfb4c4cd93acfd97776160afe
InstanceOf: List

* insert efd5322cfb4c4cd93acfd97776160afeListRuleset
    